163 related articles for article (PubMed ID: 10702887)
1. Effect of omeprazole on the metabolism of cilostazol.
Suri A; Bramer SL
Clin Pharmacokinet; 1999; 37 Suppl 2():53-9. PubMed ID: 10702887
[TBL] [Abstract][Full Text] [Related]
2. Effects of CYP3A inhibition on the metabolism of cilostazol.
Suri A; Forbes WP; Bramer SL
Clin Pharmacokinet; 1999; 37 Suppl 2():61-8. PubMed ID: 10702888
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.
Bramer SL; Suri A
Clin Pharmacokinet; 1999; 37 Suppl 2():41-51. PubMed ID: 10702886
[TBL] [Abstract][Full Text] [Related]
4. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics.
Bramer SL; Forbes WP
Clin Pharmacokinet; 1999; 37 Suppl 2():13-23. PubMed ID: 10702883
[TBL] [Abstract][Full Text] [Related]
5. Effect of multiple cilostazol doses on single dose lovastatin pharmacokinetics in healthy volunteers.
Bramer SL; Brisson J; Corey AE; Mallikaarjun S
Clin Pharmacokinet; 1999; 37 Suppl 2():69-77. PubMed ID: 10702889
[TBL] [Abstract][Full Text] [Related]
6. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease.
Bramer SL; Forbes WP; Mallikaarjun S
Clin Pharmacokinet; 1999; 37 Suppl 2():1-11. PubMed ID: 10702882
[TBL] [Abstract][Full Text] [Related]
7. Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolites.
Mallikaarjun S; Forbes WP; Bramer SL
Clin Pharmacokinet; 1999; 37 Suppl 2():33-40. PubMed ID: 10702885
[TBL] [Abstract][Full Text] [Related]
8. Effect of hepatic impairment on the pharmacokinetics of a single dose of cilostazol.
Bramer SL; Forbes WP
Clin Pharmacokinet; 1999; 37 Suppl 2():25-32. PubMed ID: 10702884
[TBL] [Abstract][Full Text] [Related]
9. Interaction potential and tolerability of the coadministration of cilostazol and aspirin.
Mallikaarjun S; Forbes WP; Bramer SL
Clin Pharmacokinet; 1999; 37 Suppl 2():87-93. PubMed ID: 10702891
[TBL] [Abstract][Full Text] [Related]
10. Effect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarin.
Mallikaarjun S; Bramer SL
Clin Pharmacokinet; 1999; 37 Suppl 2():79-86. PubMed ID: 10702890
[TBL] [Abstract][Full Text] [Related]
11. In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms.
Abbas R; Chow CP; Browder NJ; Thacker D; Bramer SL; Fu CJ; Forbes W; Odomi M; Flockhart DA
Hum Exp Toxicol; 2000 Mar; 19(3):178-84. PubMed ID: 10889516
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of multiple-dose oral cilostazol in middle-age and elderly men and women.
Suri A; Forbes WP; Bramer SL
J Clin Pharmacol; 1998 Feb; 38(2):144-50. PubMed ID: 9549645
[TBL] [Abstract][Full Text] [Related]
13. Potential interactions between cilostazol and probucol: a two-part, single-dose, open-label study in healthy Korean male volunteers.
Kim KP; Kim BH; Lim KS; Kim TE; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Oct; 31(10):2098-106. PubMed ID: 19922880
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of vatiquinone drug-drug interaction potential in vitro and in a phase 1 clinical study with tolbutamide, a CYP2C9 substrate, and omeprazole, a CYP2C19 substrate, in healthy subjects.
Murase K; Lee L; Ma J; Barrett R; Thoolen M
Eur J Clin Pharmacol; 2022 Nov; 78(11):1823-1831. PubMed ID: 36166059
[TBL] [Abstract][Full Text] [Related]
15. Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites.
Lee HI; Byeon JY; Kim YH; Lee CM; Choi CI; Jang CG; Bae JW; Lee YJ; Lee SY
Eur J Clin Pharmacol; 2018 Nov; 74(11):1417-1426. PubMed ID: 30039199
[TBL] [Abstract][Full Text] [Related]
16. The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man.
Akiyama H; Kudo S; Shimizu T
Arzneimittelforschung; 1985; 35(7A):1133-40. PubMed ID: 4074424
[TBL] [Abstract][Full Text] [Related]
17. Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects.
Fang AF; Damle BD; LaBadie RR; Crownover PH; Hewlett D; Glue PW
Pharmacotherapy; 2008 Jan; 28(1):42-50. PubMed ID: 18154473
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans.
Woo SK; Kang WK; Kwon KI
Clin Pharmacol Ther; 2002 Apr; 71(4):246-52. PubMed ID: 11956507
[TBL] [Abstract][Full Text] [Related]
19. Effect of Omeprazole on the Pharmacokinetics of Rosuvastatin in Healthy Male Volunteers.
Shah Y; Iqbal Z; Ahmad L; Khuda F; Khan A; Khan A; Khan MI; Ismail
Am J Ther; 2016; 23(6):e1514-e1523. PubMed ID: 25719441
[TBL] [Abstract][Full Text] [Related]
20. Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
Kletzl H; Giraudon M; Ducray PS; Abt M; Hamilton M; Lum BL
Anticancer Drugs; 2015 Jun; 26(5):565-72. PubMed ID: 25643050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
